Acadian Asset Management LLC Has $2.23 Million Stake in Sensus Healthcare, Inc. $SRTS

Key Points

• Acadian Asset Management LLC increased its stake in Sensus Healthcare, Inc. by 35.3%, owning 470,713 shares valued at approximately $2.225 million as of the end of the last quarter.
• Research analysts have mixed sentiments on Sensus Healthcare, with target prices cut by several firms; the average target price is now $8.00 despite a general "Buy" rating among analysts.
• Sensus Healthcare reported a net loss of ($0.06) earnings per share last quarter, missing the analysts' estimates, and generated quarterly revenue of $7.32 million, below expectations of $9.30 million.

Acadian Asset Management LLC grew its holdings in shares of Sensus Healthcare, Inc. (NASDAQ:SRTS - Free Report) by 35.3% in the first quarter, according to its most recent filing with the SEC. The firm owned 470,713 shares of the company's stock after acquiring an additional 122,746 shares during the quarter. Acadian Asset Management LLC owned about 2.85% of Sensus Healthcare worth $2,225,000 as of its most recent SEC filing.

Other institutional investors also recently added to or reduced their stakes in the company. Wealth Enhancement Advisory Services LLC acquired a new position in Sensus Healthcare during the 1st quarter worth $71,000. Millennium Management LLC boosted its position in Sensus Healthcare by 256.6% during the 4th quarter. Millennium Management LLC now owns 85,329 shares of the company's stock worth $590,000 after acquiring an additional 61,403 shares during the period. IFP Advisors Inc boosted its position in Sensus Healthcare by 37.2% during the 1st quarter. IFP Advisors Inc now owns 18,800 shares of the company's stock worth $89,000 after acquiring an additional 5,100 shares during the period. Pacific Ridge Capital Partners LLC acquired a new position in Sensus Healthcare during the 1st quarter worth $542,000. Finally, Bank of New York Mellon Corp boosted its position in Sensus Healthcare by 3.9% during the 1st quarter. Bank of New York Mellon Corp now owns 141,971 shares of the company's stock worth $672,000 after acquiring an additional 5,289 shares during the period. Institutional investors and hedge funds own 25.30% of the company's stock.

Sensus Healthcare Trading Down 1.0%

SRTS stock traded down $0.03 during mid-day trading on Friday, hitting $3.11. The stock had a trading volume of 138,246 shares, compared to its average volume of 85,961. Sensus Healthcare, Inc. has a 1-year low of $3.03 and a 1-year high of $9.33. The company has a fifty day moving average of $3.92 and a 200 day moving average of $4.41. The stock has a market capitalization of $51.13 million, a price-to-earnings ratio of -51.83 and a beta of 1.41.

Sensus Healthcare (NASDAQ:SRTS - Get Free Report) last issued its earnings results on Thursday, August 7th. The company reported ($0.06) earnings per share for the quarter, missing the consensus estimate of $0.01 by ($0.07). Sensus Healthcare had a negative return on equity of 1.58% and a negative net margin of 2.26%.The firm had revenue of $7.32 million during the quarter, compared to analyst estimates of $9.30 million. As a group, sell-side analysts expect that Sensus Healthcare, Inc. will post 0.32 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several brokerages have recently weighed in on SRTS. HC Wainwright cut their price objective on Sensus Healthcare from $12.00 to $8.00 and set a "buy" rating for the company in a report on Tuesday, August 12th. Wall Street Zen lowered Sensus Healthcare from a "hold" rating to a "sell" rating in a report on Sunday, June 22nd. Finally, Lake Street Capital cut their price objective on Sensus Healthcare from $13.00 to $6.00 and set a "buy" rating for the company in a report on Friday, August 8th. Three research analysts have rated the stock with a Buy rating, Based on data from MarketBeat.com, the stock currently has a consensus rating of "Buy" and a consensus price target of $8.00.

Sensus Healthcare Company Profile

Sensus Healthcare, Inc, a medical device company, manufactures and sells radiation therapy devices to healthcare providers worldwide. The company uses superficial radiation therapy, a low-energy X-ray technology in its portfolio of treatment devices. It offers SRT-100, a photon X-ray low energy superficial radiotherapy system that provides patients an alternative to surgery for treating non-melanoma skin cancers, including basal cell and squamous cell skin cancers, as well as other skin conditions, such as keloids; and SRT-100 Vision, which provides the user with a superficial radiation therapy-tailored treatment planning application that integrates an embedded high frequency ultrasound imaging module, volumetric tumor analysis, beam margins planning, and dosimetry parameters.